RxDoctor Payments Data

Gerald Lee

Internal Medicine · Harrington Park, NJNPI 1982692745

Payments from drug & device makers

$12,034in general payments, 2019–2025

Across 781 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$662
  • GSK$579
  • AstraZeneca$565
  • AbbVie$558
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,97199%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)219$2,739
Novo Nordisk93$1,501
Lilly USA, LLC41$662
GSK37$579
AstraZeneca(2 entities)31$565
AbbVie39$558
Merck38$511
Johnson & Johnson(2 entities)27$510
Pfizer24$359
Boehringer Ingelheim18$269
Sanofi-aventis U.S. LLC14$233
Abbott5$189
Kowa Pharmaceuticals America, Inc.13$187
Exact Sciences8$183
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$149
Boston Scientific3$144
Madrigal Pharmaceuticals7$143
Corcept Therapeutics6$142
Otsuka America Pharmaceutical, Inc.8$142
Eisai Inc.9$131
Amarin Pharma, Inc.8$112
Incyte Corporation1$104
Harmony Biosciences LLC7$101
Takeda Pharmaceuticals U.S.A., Inc.6$97
Gilead6$82
Bayer4$77
Phathom Pharmaceuticals, Inc.5$74
Endo Pharmaceuticals Inc.5$71
Lundbeck LLC4$70
Redhill Biopharma Inc.5$69
Teva Pharmaceuticals USA, Inc.4$64
Bausch Health US, LLC4$64
Idorsia Pharmaceuticals US Inc4$63
QOL Medical, LLC4$60
Biohaven Pharmaceutical Holding Company Ltd.4$59
Jazz Pharmaceuticals Inc.4$56
Tolmar, Inc.3$53
Amneal Pharmaceuticals LLC4$53
Arbor Pharmaceuticals, Inc.1$52
Sanofi Pasteur Inc.3$45
Philips North America LLC2$41
Insulet Corporation2$40
Novartis2$35
Medtronic1$33
Currax Pharmaceuticals LLC2$32
Mannkind Corporation2$30
Vivus LLC2$29
Xeris Pharmaceuticals, Inc.2$29
Daiichi Sankyo Inc.2$28
Acerus Pharmaceuticals Corporation2$26
Shire North American Group Inc2$25
RGH Enterprises LLC1$24
Astellas Pharma US Inc1$22
IBSA Pharma Inc.1$19
Mallinckrodt Hospital Products Inc.1$19
Inspire Medical Systems, Inc.1$19
Lexicon Pharmaceuticals, Inc.1$17
Seqirus USA Inc1$17
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Cequr Corporation1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,034 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$178,494
Medicare patients
392
Services billed
3,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$160,957
JardianceEmpagliflozin73$96,690
MounjaroTirzepatide77$85,193
JanuviaSitagliptin Phosphate77$75,202
EliquisApixaban33$33,508
FarxigaDapagliflozin Propanediol23$26,942
XareltoRivaroxaban23$17,926
VascepaIcosapent Ethyl19$9,257
Repatha SureclickEvolocumab14$7,867
Rosuvastatin Calcium466$7,025
Atorvastatin Calcium639$6,518
LinzessLinaclotide11$6,368
BenicarOlmesartan Medoxomil12$3,669
Olmesartan Medoxomil125$3,545
Amlodipine Besylate487$3,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,501$160,957118 claims
Boehringer IngelheimJardiance$269$96,69073 claims
Lilly USA, LLCMounjaro$662$85,19377 claims
MerckJanuvia$511$75,20277 claims
PfizerEliquis, Paxlovid$359$36,36653 claims
AstraZenecaFarxiga$565$26,94223 claims
Johnson & JohnsonXarelto$510$17,92623 claims
AbbVieLinzess, Synthroid$558$7,78228 claims
Daiichi Sankyo Inc.Benicar$28$3,66912 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$53$1,507174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Harrington Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →